Abstract: Compositions that contain enriched amounts of Withanolides are provided. Such compositions will include natural extracts of Ashwagandha (Withania somnifera), including whole plant extracts and/or root extracts, which have been supplemented with or contain elevated amounts of Withanolide A, Withanolide B, Withanolide D, Withaferin A, Withanoside IV, and/or Withanoside V. Methods for modulating GPX1, Nrf2, HO1, mTOR, TERT, ?-Catenin, and/or NF-?B using such Withanolide-enriched compositions are also disclosed, as well as using such Withanolide-enriched compositions to stimulate hair growth.

Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.

Abstract: Compositions that contain enriched amounts of Withanolides are provided. Such compositions will include, consist essentially of, or consist entirely of natural extracts of Ashwagandha (Withania somnifera), including whole plant extracts and/or root extracts, which have been supplemented with additional amounts of Withanolide A, Withanolide B, Withanolide D, Withaferin A, Withanoside IV, and/or Withanoside V. The additional amounts of such Withanolides that are added to the Ashwagandha extracts may be naturally occurring isolates or synthetic versions of such Withanolides, such that the total/final Withanolide concentration is at least ten (10%)(w/w)—but may include even higher concentrations of such Withanolides. Methods for modulating GPX1, Nrf2, HO1, mTOR, TERT, ?-Catenin, and/or NF-KB using such Withanolide-enriched compositions are also disclosed.

Abstract: Natural sweetener compositions are disclosed, which generally include various combinations of steviol glycosides extracted from a Stevia rebaudiana plant; Siraitia grosvenorii (Monk Fruit) plant extract (including mogrosides extracted from such plant species); and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally further include gymnemic acid (such as an extract of a Gymnemic sylvestre herb that includes 25%-75% gymnemic acid). The natural sweetener compositions may consist essentially of those two, three, or four components—or may be included in beverages, beverage powders, and foods.

Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.

Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.

Abstract: Natural sweetener compositions are disclosed, which generally include steviol glycosides extracted from a Stevia rebaudiana plant and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally further include gymnemic acid (such as an extract of a Gymnemic sylvestre herb that includes 25%-75% gymnemic acid). The natural sweetener compositions may consist essentially of those two or three components—or may be included in beverages, beverage powders, and foods.

Abstract: Natural sweetener compositions are disclosed, which generally include various combinations of steviol glycosides extracted from a Stevia rebaudiana plant; Siraitia grosvenorii (Monk Fruit) plant extract (including mogrosides extracted from such plant species); and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally further include gymnemic acid (such as an extract of a Gymnemic sylvestre herb that includes 25%-75% gymnemic acid). The natural sweetener compositions may consist essentially of those two, three, or four components—or may be included in beverages, beverage powders, and foods.

Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.

Abstract: Methods for modulating miRNA148a levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III in order to increase miRNA148a levels, or providing to the cells a curcumin II-enriched composition in order to reduce miRNA148a levels. In addition, compositions for elevating miRNA148a levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 5% curcumin III and a pharmaceutically-acceptable solvent, filler, or carrier. Similarly, compositions for reducing miRNA148a levels in a plurality of cells are disclosed, which include a curcumin II-enriched composition and a pharmaceutically-acceptable solvent, filler, or carrier.

Abstract: Methods for reducing MSK1 levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III. Methods for inhibiting MSK1 serine376 phosphorylation in a plurality of cells are also disclosed, which include providing to the cells a curcumin composition that is at least 5% curcumin III. In addition, methods for ameliorating inflammation in a subject are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. Still further, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. In addition, compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier.

Abstract: Methods for modulating miRNA148a levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III, in order to increase miRNA148a levels. In addition, compositions for elevating miRNA148a levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 5% curcumin III and a pharmaceutically-acceptable solvent, filler, or carrier.

Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Abstract: Methods for reducing MSK1 levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III. Methods for inhibiting MSK1 serine376 phosphorylation in a plurality of cells are also disclosed, which include providing to the cells a curcumin composition that is at least 5% curcumin III. In addition, methods for ameliorating inflammation in a subject are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. Still further, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. In addition, compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier.

Abstract: Compositions are disclosed that include undenatured whey protein and glycine. The undenatured whey protein is preferably included at a final concentration of about 20%-80%, while the glycine is present at a final concentration of about 5%-35%. The whey protein has not been exposed to acid hydrolysis and, preferably, includes cold cross-flow membrane filtrate. The glycine is preferably 20-80 mesh in size, and exhibits a U.S. Pharmacopeia (USP) 28 grade. The composition further includes several vitamin and mineral cofactors, namely, selenomethionine, nicotinamide adenine dinucleotide (NADH), and Vitamin B3.

Abstract: Compositions that include vanadium or vanadyl chelated to an amino acid are disclosed, particularly vanadium or vanadyl chelated to creatine, arginine, citrulline, taurine, phenylalanine, glutamine, glutathione, leucine, or combinations thereof. In addition, compositions that included blended forms of such chelates and/or vanadyl sulfate and one or more unbound amino acids. Still further, the compositions disclosed may further include one or more additional proteins, amino acids, vitamins, minerals, or combinations thereof, which impart an additional nutritional and/or therapeutic benefit to the composition.